BioAge Labs, Inc. (BIOA)

BioAge Labs, Inc. (BIOA) is a healthcare company (drug manufacturers - specialty & generic) based in the United States. The share price is $5.12, down 2.01% on the day, which values the company at $235.04M. Price as of 17 Nov 2026, 18:09 UTC, from Yahoo Finance.

Key facts

Share price
$5.12−2.01% today
Market value
$235.04M
Sector
Healthcare

Figures as of . Prices from Yahoo Finance (may be delayed); statements from company filings with the SEC and Yahoo Finance. Estimates, not advice.

BioAge Labs, Inc. in more detail

BIOA trades at -2.0× next year's expected earnings, 27.3× sales.

In its favour: Altman Z in the safe zone; More cash than debt. Worth checking: Weak Piotroski score; Thin interest cover.

1 of the superinvestors tracked here hold BIOA, including Peter Kolchinsky (0.4% of the portfolio).

Superinvestors holding BIOA

1 of the investors tracked here report a position in their latest 13F filing.

BioAge Labs, Inc. (BIOA): questions and answers

What is BioAge Labs, Inc.'s market cap?

BioAge Labs, Inc. is valued at $235.04M at a share price of $5.12.

Does BIOA pay a dividend?

BioAge Labs, Inc. does not currently pay a regular dividend.

Which famous investors own BIOA?

In their latest quarterly filings, Peter Kolchinsky (0.4% of the portfolio) hold BIOA. These filings are published up to 45 days after each quarter ends, so positions may have changed since.

Cite this page

Funkfolio, “BioAge Labs, Inc. (BIOA) stock: price, valuation and fundamentals”, data as of 17 November 2026. https://funkfolio.com/stock/BIOA

Underlying data: Yahoo Finance; company filings with the SEC.